Juridical Foundation the Chemo-Sero-Therapeutic Research Institute

Km Biologics Co., Ltd.

Kowa Company Limited

Kazuhiko Kimachi

Hiroaki Maeda

Sachio Tokiyoshi

Yasuyuki Eda

Kiyoto Nishiyama

Yoichi Ono

Kazuyuki Ikeda

Kiyoshi Osatomi

Motoharu Abe

Kouichi Shiosaki

Hiroto Onuma

Yukari Tsurudome

Toshihiro Nakashima

Masao Ohkuchi

Tomoyuki Koshi

Toshiyuki Edano

Hirofumi Higuchi

Tsukasa Nishihara

Hiroshi Yonemura

Takumi Sasaki

Keiichi Makizumi

Yoichiro Kino

Takeshi Mikami

Yuji Ishikawa

Ryo Yamaue

Atsuko Sakata

Yukinobu Tohya

Makoto Moriyama

Shigeki Kuwata

Ryoichi Kitano

Issay Asano

Yusuke Ooyama

Tatsufumi Onchi

Daisuke Ikeno

Yuki Ohara

Akihiro Watanabe

Yuki Mihara

Katsuhiko Fukada

A method for preparing a PRP conjugate having high storage stability and a method for producing a Hib conjugate vaccine are provided. A method for preparing PRP conjugate in accordance with the embodiments of the present invention is characterized by that the release of PRPs after preparing the PRP conjugate is suppressed by using PRP with a lowered molecular weight than native PRP for a coupling reaction between PRP and a carrier protein. Also, a Hib conjugate vaccine comprising as an antigen the PRP conjugate prepared by said method has excellent storage stability and maintain sufficient immunogenicity.

Method for producing Hib conjugate vaccine using PRP with lowered molecular weight

The present invention relates to a vaccine containing fixed virus particles, wherein a summed fever response of three rabbits to the fixed virus particles in a pyrogen test is less than 80% based on a summed fever response of three rabbits to original virus particles of the fixed virus particles or corresponding inactivated virus particles.

Vaccine containing immobilized virus particles

The present invention provides a vaccine containing virus-like particles derived from virus particles having an envelope, in which a lipid-component content of the virus-like particles is reduced relative to a lipid-component content of the virus particles.

Vaccine containing virus-like particles

A novel prophylactic/remedy for immunopathy is provided which is not neutralized by a neutralizing antibody to Staphylococcal enterotoxin B (SEB), known as one of superantigens, and may effectively act as a superantigen. A modified SEB having a reduced reactivity with a neutralizing antibody to SEB (anti-SEB antibody) and a prophylactic/remedy for immunopathy comprising as an active ingredient said modified SEB. The modified SEB of the present invention may be prepared with the evolutionary molecular engineering technique by introducing amino acid substitution in the amino acid sequence of SEB, especially at an epitope recognition site of the anti-SEB antibody in the amino acid sequence of SEB.

Modified SEB and prophylactics/remedies for immunopathy containing the same

Anti-HIV monoclonal antibody

A Gene fragment which comprises a DNA sequence coding for an amino acid sequence of a constant region of feline immunoglobulin .lambda. chain; a gene fragment which comprises a DNA sequence coding for an amino acid sequence of a constant region of feline immunoglobulin .kappa. chain; a gene fragment which comprises a DNA sequence coding for the constant region of feline immunoglobulin .gamma. chain; a recombinant DNA molecule coding for an amino acid sequence of a mouse-cat chimeric antibody which comprises a gene fragment coding for an amino acid sequence of a variable region of a mouse immunoglobulin and a gene fragment coding for an amino acid sequence of a constant region of a feline immunoglobulin wherein the latter gene fragment is linked to the 3' site of the former gene fragment; a polypeptide of a mouse-cat chimeric antibody which is expressed from a cell transformed with an expression vector for cells wherein said recombinant DNA molecule coding for an amino acid sequence of the mouse-cat chimeric antibody is incorporated; a cat-mouse heterohybridoma which produces feline immunoglobulin; and a process for preparing a feline immunoglobulin gene.

Cat-mouse heterohybridoma and gene fragment coding for constant region

A gene fragment which comprises a DNA sequence coding for an amino acid sequence of a constant region of canine immunoglobulin lambda chain; a gene fragment which comprises a DNA sequence coding for an amino acid sequence of a constant region of canine immunoglobulin kappa chain; a gene fragment which comprises a DNA sequence coding for the constant region of canine immunoglobulin gamma chain; a recombinant DNA molecule coding for an amino acid sequence of a mouse-dog chimeric antibody which comprises a gene fragment coding for an amino acid sequence of a variable region of a mouse immunoglobulin and a gene fragment coding for an amino acid sequence of a constant region of a canine immunoglobulin wherein the latter gene fragment; a polypeptide of a mouse-dog chimeric antibody which is expressed from a cell transformed with an expression vector for cells wherein said recombinant DNA molecule cording for an amino acid sequence of the mouse-dog chimeric antibody is incorporated; a dog-mouse heterohybridoma which produces canine immunoglobulin; and a process for preparing a canine immunoglobulin gene.

Dog-mouse heterohybridoma and gene fragment coding for constant region

Anti-FCV (feline calicivirus) feline-type recombinant antibody effective for treatment, prevention and diagnosis of FCV infection and a gene fragment useful for preparation of said antibody are provided. Cell line 1D7 capable of producing a mouse monoclonal antibody having an excellent FCV-neutralizing activity was constructed and a gene fragment coding for the V region in charge of the FCV-specific binding of said antibody was obtained. This gene fragment and the gene coding for the constant region of the feline antibody are used to give a chimeric anti-FCV recombinant antibody. The obtained recombinant antibody is a novel antibody and is useful for the diagnosis, treatment and prevention of feline virus infections, particularly feline calicivirus infection, with high safety in administration into cats.

Anti-feline calicivirus recombinant antibody and gene fragment encoding

Recombinant anti-HIV antibody and process for preparing the same

Anti-feline herpes virus-1 recombinant antibody and gene fragment coding

Method for producing exogenous protein

A gene fragment which comprises a DNA sequence coding for an amino acid sequence of a constant region of canine immunoglobulin lambda chain; a gene fragment which comprises a DNA sequence coding for an amino acid sequence of a constant region of canine immunoglobulin kappa chain; a gene fragment which comprises a DNA sequence coding for the constant region of canine immunoglobulin gamma chain; a recombinant DNA molecule coding for an amino acid sequence of a mouse-dog chimeric antibody which comprises a gene fragment coding for an amino acid sequence of a variable region of a mouse immunoglobulin and a gene fragment coding for an amino acid sequence of a constant region of a canine immunoglobulin; a polypeptide of a mouse-dog chimeric antibody which is expressed from a cell transformed with an expression vector for cells wherein said recombinant DNA molecule cording for an amino acid sequence of the mouse-dog chimeric antibody is incorporated; a dog-mouse heterohybridoma which produces canine immunoglobulin; and a process for preparing a canine immunoglobulin gene.

Growing community of inventors

Kumamoto, Japan

Kazuhiko Kimachi